Dividends & Buybacks ·
On July 29, 2026, Genenta Science S.p.A. held an Extraordinary Shareholders’ Meeting where the proposal to change its…
GNTAGenenta Science S.p.A.
On July 29, 2026, Genenta Science S.p.A. held an Extraordinary Shareholders’ Meeting where the proposal to change its corporate name to Saentra Forge S.p.A. was deferred pending further evaluation of branding strategy and shareholder consultations; this revised proposal will be considered at a reconvened meeting on September 10 or 11, 2026. Shareholders approved a delegation granting the Board authority for five years to increase share capital by up to €300 million, issue up to 120 million new ordinary shares, and issue convertible bonds for strategic transactions or capital raises. Additionally, shareholders authorized a reverse stock split within a range of 1-for-10 to 1-for-20 to help maintain compliance with Nasdaq’s minimum bid price requirement, with the Board empowered to determine the specific ratio, effective date, and implementation details within twelve months. Genenta Science S.p.A. operates in the biotechnology industry, focusing on the development of therapies for rare diseases.